TRV GP Iii LLC Has $71.07 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

TRV GP Iii LLC lowered its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating) by 29.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,604,130 shares of the company’s stock after selling 1,500,000 shares during the quarter. Revolution Medicines makes up approximately 31.0% of TRV GP Iii LLC’s holdings, making the stock its 2nd biggest holding. TRV GP Iii LLC owned approximately 4.11% of Revolution Medicines worth $71,073,000 at the end of the most recent reporting period.

→ My No. 1 dividend stock for a LIFETIME of income. (From Oxford Club)

A number of other hedge funds have also made changes to their positions in RVMD. MetLife Investment Management LLC increased its position in shares of Revolution Medicines by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 34,256 shares of the company’s stock worth $874,000 after purchasing an additional 12,643 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Revolution Medicines by 165.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 478,776 shares of the company’s stock valued at $12,214,000 after acquiring an additional 298,436 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Revolution Medicines by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 444,212 shares of the company’s stock valued at $11,332,000 after acquiring an additional 13,134 shares in the last quarter. Northern Trust Corp increased its position in Revolution Medicines by 12.3% in the 1st quarter. Northern Trust Corp now owns 629,849 shares of the company’s stock valued at $16,067,000 after acquiring an additional 68,794 shares in the last quarter. Finally, State Street Corp increased its position in Revolution Medicines by 3.2% in the 1st quarter. State Street Corp now owns 2,843,477 shares of the company’s stock valued at $72,537,000 after acquiring an additional 88,844 shares in the last quarter.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded down $0.43 during mid-day trading on Friday, hitting $27.18. The company’s stock had a trading volume of 1,501 shares, compared to its average volume of 1,037,492. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -8.68 and a beta of 1.49. Revolution Medicines, Inc. has a one year low of $14.08 and a one year high of $31.37. The company’s fifty day simple moving average is $23.59 and its 200-day simple moving average is $22.00.

Revolution Medicines (NASDAQ:RVMD – Get Rating) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.87) earnings per share for the quarter, hitting the consensus estimate of ($0.87). Revolution Medicines had a negative net margin of 829.80% and a negative return on equity of 41.97%. The business had revenue of $3.36 million for the quarter, compared to analyst estimates of $8.57 million. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -3.31 EPS for the current year.

Insider Buying and Selling

In related news, insider Margaret A. Horn sold 17,768 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, October 26th. The shares were sold at an average price of $20.15, for a total transaction of $358,025.20. Following the transaction, the insider now owns 35,534 shares of the company’s stock, valued at approximately $716,010.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Revolution Medicines news, COO Margaret A. Horn sold 17,767 shares of Revolution Medicines stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $20.41, for a total value of $362,624.47. Following the transaction, the chief operating officer now owns 17,767 shares of the company’s stock, valued at $362,624.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Margaret A. Horn sold 17,768 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, October 26th. The shares were sold at an average price of $20.15, for a total transaction of $358,025.20. Following the completion of the transaction, the insider now directly owns 35,534 shares in the company, valued at approximately $716,010.10. The disclosure for this sale can be found here. Insiders have sold 36,901 shares of company stock valued at $751,986 in the last 90 days. 18.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Oppenheimer assumed coverage on shares of Revolution Medicines in a research report on Thursday, October 20th. They issued an “outperform” rating and a $30.00 price objective for the company. HC Wainwright raised their target price on shares of Revolution Medicines from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, December 8th. Finally, Needham & Company LLC assumed coverage on shares of Revolution Medicines in a research note on Wednesday, December 14th. They issued a “buy” rating and a $31.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Revolution Medicines Profile

(Get Rating)

Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.

Featured Articles

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Get Rating).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Revolution Medicines, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revolution Medicines wasn’t on the list.

While Revolution Medicines currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover